Navigation Links
Medbox Communicates with Shareholders, Comments on Pending Transition to OTC Bulletin Board, and Announces Appearance on Fox Business News Channel
Date:11/19/2012

HOLLYWOOD, Calif., Nov. 19, 2012 /PRNewswire/ -- Medbox, Inc. (Ticker: MDBX) (www.medboxinc.com), announced that following their most recent press release they have received many inquiries from shareholders purchasing shares of MDBX from 3rd parties during last week's volatile trading. These inquiries were responded to and shareholders were content with the company's commitment to shareholder rapport.

In other news, the company further identified their exact plans as to moving from the OTC Market to the OTC Bulletin Board and becoming a fully reporting public company meeting all SEC requirements. At present the company is a "Current" OTC Market stock which means they voluntarily file reports and post financials on the OTC markets website for the public to view. The company's attorneys have already begun the process of preparing the S-1 registration statement for filing with the SEC and are in the midst of a public audit, as to the company's prior 3 years of financials, which will be complete at the end of 2012. The company has contracted with a public auditing firm that specializes in these types of internal audits and is accredited with the highest classification awarded to CPA's - the Chartered Global Management Accountant (CGMA) credential. These steps are necessary to up-list exchanges. The company will be filing its S-1 and will have completed its internal audit within Q1 2013.

"In one facet of our business, we sell technology that allows medical marijuana dispensaries to operate in the most transparent means possible with total accountability.  It would be inconsistent of us as a company to not meet a similar level of scrutiny - and that is why we are looking forward to our internal audit in furtherance of our transition to the OTC Bulletin Board," stated Dr. Bruce Bedrick, CEO of Medbox, Inc.

In other news, the company announced that Dr. Bedrick will be appearing on Fox Business News Channel at 5pm EST today to discuss the company's stock, the medical marijuana industry, and uses of the company's technology in pharmacies, urgent-care centers, and prisons for standard prescription dispensing.

For more information, contact Medbox Investor Relations at: (800) 762-1452.

About Medbox, Inc: 
Medbox is a leader in the development, sales and service of automated, biometrically controlled dispensing and storage systems for medicine and merchandise. Medbox has offices throughout the world, including New York, Arizona, Connecticut, Massachusetts, Tokyo, London and Toronto, and has their corporate headquarters in Los Angeles.

Medbox provides their patented systems, software and consulting services to pharmacies, dispensaries, urgent care centers, drug rehab clinics, hospitals, prison systems, hospice facilities, and medical groups worldwide.

Medbox, Inc. is a publicly traded company, and is listed on the OTC Board, ticker symbol MDBX.

For more information on Medbox, please contact the Medbox Investor Relations Department at (800) 762-1452 or go online to www.thedispensingsolution.com


'/>"/>
SOURCE Medbox, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology news :

1. AVT Develops Biometrically Secure Medicine Storage and Retrieval System for Medbox RX
2. Medbox, Inc. Releases 2nd Quarter Financials
3. Medbox Safe Storage and Access Lockers Gaining Popularity
4. Medbox Developing a Patent Pending Wall-Mounted Biometric Kiosk for Storage of Sensitive Medicine Samples and Supplies for Doctors Offices.
5. Medbox, Inc. Announces Top-Tier Rating by Dun & Bradstreet Credibility Corporation
6. Jekyll and Hyde bacteria aids or kills, depending on chance
7. Malaysia to battle nutrition transition problem emerging worldwide: More income, poorer diet choices
8. Summer Geoscience from GSA Bulletin
9. GSA Bulletin presents studies in Antarctica, Italy, Mexico, Algeria, Mongolia, and more
10. Diabetes Management Provider ActiveCare Announces Cost Savings Of Over $4,000 Per Year Per Diabetic Member
11. SETAC announces Chris Lee Award for metals research winner, Kevin Brix
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2016)... According to a new market research report "Emotion Detection ... Voice Recognition), Service, Application Area, End User, And Region - Global Forecast to ... 6.72 Billion in 2016 to USD 36.07 Billion by 2021, at a Compound ... ... MarketsandMarkets Logo ...
(Date:12/7/2016)... LONDON , Dec. 7, 2016   Avanade ... most successful Formula One teams in history, exploit biometric ... pit stop performance and maintain the competitive edge against ... in 2016. Avanade has worked with ... a range of biometric data (heart rate, breathing rate, ...
(Date:12/6/2016)... , Dec. 6, 2016  Zimmer Biomet Holdings, Inc. ... has priced an offering of €500.0 million principal amount of ... principal amount of its 2.425% senior unsecured notes due 2026. ... to occur on December 13, 2016, subject to the satisfaction of ... annual basis. The Company intends ...
Breaking Biology News(10 mins):
(Date:12/8/2016)... Oregon (PRWEB) , ... December 08, 2016 , ... ... and the FrontPanel SDK that provide essential device-to-computer interconnect using USB or PCI ... not require FrontPanel support. The FOMD-ACV-A4 is a small, thin, SODIMM-style module that ...
(Date:12/8/2016)... ... December 08, 2016 , ... ... packaging for their exceptionally efficient human mesenchymal stem/stromal cell (hMSC) expansion medium. ... bioprocess media products engineered to radically streamline culture processes, minimize processing time, ...
(Date:12/8/2016)... 2016  HedgePath Pharmaceuticals, Inc. (OTCQX: HPPI), a ... plans to commercialize innovative therapeutics for patients with ... were approved for trading on the OTCQX U.S. ... OTCQX, effective today, under the ticker symbol "HPPI." ... companies must meet high financial standards, follow best ...
(Date:12/7/2016)... ... December 07, 2016 , ... ACEA Biosciences, Inc. presented today ... clinical trial for its lead drug candidate, AC0010, at the World Conference on ... to determine the safety, antitumor activity, and recommended phase II dosage of AC0010 ...
Breaking Biology Technology: